Ascletis Pharma, Inc.
Ascletis Pharma, Inc. (1672) is a biotechnology company focused on the research, development, and commercialization of innovative therapies for the treatment of viral diseases, particularly hepatitis B virus (HBV) and hepatitis C virus (HCV), as well as oncology. The company operates primarily in the pharmaceutical sector and emphasizes the development of novel antiviral drugs and treatments that address significant unmet medical needs. Ascletis is committed to advancing its proprietary drug candidates through clinical trials to achieve regulatory approvals and market release.